“Iso fentanyl” is a street name for isotonitazene, a synthetic opioid that belongs to a completely different chemical class than fentanyl. Despite the nickname, isotonitazene is not a form of fentanyl at all. It’s a benzimidazole opioid, part of a family called nitazenes, and lab testing shows it activates opioid receptors roughly 200 times more potently than fentanyl. It has no approved medical use and is classified as a Schedule I controlled substance in the United States.
Why It’s Called “Iso Fentanyl”
The name “iso fentanyl” spread as isotonitazene began appearing in the illicit drug supply, often mixed into or sold as fentanyl. Because users and dealers encountered it in the same powder, pill, and solution forms as fentanyl, the shorthand stuck. But the chemistry is entirely different. Fentanyl is a piperidine-based opioid originally developed for surgical pain management. Isotonitazene is a benzimidazole compound first synthesized decades ago for research purposes and never approved for any medical or veterinary use. They share one thing: both powerfully activate the body’s primary opioid receptor, the one responsible for pain relief, sedation, and respiratory depression.
How Potent Isotonitazene Actually Is
In lab studies measuring how strongly a compound activates opioid receptors, isotonitazene required a concentration of just 0.02 nanomoles to reach half its maximum effect. Fentanyl needed 4.0 nanomoles, and morphine needed 34 nanomoles to do the same. That makes isotonitazene roughly 200 times more potent than fentanyl and about 1,700 times more potent than morphine at the receptor level.
This extreme potency means a quantity invisible to the naked eye can be enough to cause a fatal overdose. Because isotonitazene appears as a powder, pressed tablet, or liquid that looks identical to fentanyl or heroin, there’s no way to distinguish it by sight, smell, or taste.
Effects and Overdose Risks
Isotonitazene produces the same core effects as other opioids: pain suppression, euphoria, drowsiness, and slowed breathing. The critical danger is that the margin between a dose that gets someone high and a dose that stops their breathing is extraordinarily narrow. Animal research shows isotonitazene also stimulates the brain’s reward and movement pathways through the dopamine system, which contributes to its addictive potential.
Overdose survivors can face lasting consequences. The medical term “toxic brain injury” describes the damage that occurs when the brain is deprived of oxygen during an overdose, even a non-fatal one. This can result in short-term or permanent cognitive impairment and physical disabilities. Because people who overdose on isotonitazene are typically unconscious when found, first responders and emergency physicians have no way to know what substance was taken, which complicates treatment.
Does Naloxone Still Work?
Naloxone (the active ingredient in Narcan) does reverse isotonitazene overdoses, which is significant because there was early concern that nitazenes might be too potent for standard doses to counteract. Clinical data from emergency cases involving nitazene-class opioids found that a standard initial dose was effective in most patients. However, nearly half of those treated needed a second dose, and ongoing monitoring was necessary because the drug’s effects can return after naloxone wears off, a phenomenon called renarcotization.
If you carry naloxone, it remains your best tool in an overdose situation regardless of which opioid is involved. The key difference with isotonitazene is that one dose may not be enough, and the person may stop breathing again after initially waking up. Staying with someone after administering naloxone and calling emergency services is critical.
Standard Drug Tests Won’t Detect It
Fentanyl test strips, which have become a widely used harm reduction tool, do not detect isotonitazene or other nitazenes. The two drug classes are chemically unrelated, so a strip designed to react to fentanyl simply won’t flag a nitazene compound. A fentanyl test strip showing a negative result does not mean a sample is safe.
Dedicated nitazene test strips became commercially available in early 2024. These use a different antibody designed to react specifically to nitazene-class compounds, and they do not cross-react with fentanyl, heroin, or common cutting agents like acetaminophen or caffeine. Lab evaluation found that these strips can detect isotonitazene at concentrations of 2,000 to 3,000 nanograms per milliliter, depending on the manufacturing lot. While they represent a step forward, they’re still newer and less widely distributed than fentanyl test strips.
Where It Comes From
Nitazenes were originally synthesized in the 1950s and 1960s by researchers exploring new painkiller compounds. None were ever developed into approved medications. Isotonitazene resurfaced when it appeared on online drug markets and was first formally identified and characterized as a “novel psychoactive substance” by forensic chemists. In the years since, it has been found in the illicit drug supply across the United States, sometimes as the primary ingredient in a product, sometimes mixed with fentanyl or heroin without the buyer’s knowledge.
Along with etonitazene, clonitazene, protonitazene, and several other analogues, isotonitazene is now a Schedule I substance under the Controlled Substances Act. It can be present in powder, tablet, or liquid form and can be snorted, injected, smoked, or vaporized, making it adaptable to nearly every route of use already common in opioid markets.
Why the Distinction From Fentanyl Matters
Calling isotonitazene “iso fentanyl” creates a dangerous misunderstanding. Someone who thinks they’re dealing with a fentanyl variant might rely on fentanyl test strips that won’t detect it. They might assume their usual tolerance to fentanyl offers some protection, when isotonitazene is orders of magnitude stronger. And emergency responders who assume fentanyl may not anticipate the higher likelihood of needing repeated naloxone doses or extended monitoring.
Isotonitazene is its own class of threat. Recognizing it as a nitazene, not a fentanyl analogue, is the first step toward understanding the specific risks it carries and the specific tools needed to address them.